TTK HEALTHCARE | IPCA LABS | TTK HEALTHCARE/ IPCA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 10.7 | 24.9 | 42.9% | View Chart |
P/BV | x | 1.5 | 8.9 | 17.4% | View Chart |
Dividend Yield | % | 1.0 | 0.1 | 731.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TTK HEALTHCARE Mar-19 |
IPCA LABS Mar-19 |
TTK HEALTHCARE/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,215 | 1,042 | 116.6% | |
Low | Rs | 610 | 590 | 103.4% | |
Sales per share (Unadj.) | Rs | 444.4 | 298.6 | 148.8% | |
Earnings per share (Unadj.) | Rs | 17.2 | 35.0 | 49.3% | |
Cash flow per share (Unadj.) | Rs | 27.6 | 49.4 | 55.9% | |
Dividends per share (Unadj.) | Rs | 5.00 | 3.00 | 166.7% | |
Dividend yield (eoy) | % | 0.5 | 0.4 | 149.0% | |
Book value per share (Unadj.) | Rs | 177.9 | 247.1 | 72.0% | |
Shares outstanding (eoy) | m | 14.13 | 126.35 | 11.2% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 2.1 | 2.7 | 75.2% | |
Avg P/E ratio | x | 52.9 | 23.3 | 226.9% | |
P/CF ratio (eoy) | x | 33.0 | 16.5 | 200.1% | |
Price / Book Value ratio | x | 5.1 | 3.3 | 155.3% | |
Dividend payout | % | 29.0 | 8.6 | 338.2% | |
Avg Mkt Cap | Rs m | 12,894 | 103,108 | 12.5% | |
No. of employees | `000 | 2.3 | 13.4 | 17.2% | |
Total wages/salary | Rs m | 1,307 | 7,874 | 16.6% | |
Avg. sales/employee | Rs Th | 2,715.7 | 2,807.0 | 96.7% | |
Avg. wages/employee | Rs Th | 565.3 | 585.8 | 96.5% | |
Avg. net profit/employee | Rs Th | 105.4 | 329.0 | 32.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,279 | 37,732 | 16.6% | |
Other income | Rs m | 78 | 577 | 13.4% | |
Total revenues | Rs m | 6,356 | 38,309 | 16.6% | |
Gross profit | Rs m | 496 | 6,901 | 7.2% | |
Depreciation | Rs m | 147 | 1,824 | 8.0% | |
Interest | Rs m | 34 | 189 | 17.9% | |
Profit before tax | Rs m | 393 | 5,465 | 7.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 149 | 1,042 | 14.3% | |
Profit after tax | Rs m | 244 | 4,422 | 5.5% | |
Gross profit margin | % | 7.9 | 18.3 | 43.2% | |
Effective tax rate | % | 37.9 | 19.1 | 198.8% | |
Net profit margin | % | 3.9 | 11.7 | 33.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,717 | 23,778 | 11.4% | |
Current liabilities | Rs m | 1,571 | 10,975 | 14.3% | |
Net working cap to sales | % | 18.3 | 33.9 | 53.8% | |
Current ratio | x | 1.7 | 2.2 | 79.8% | |
Inventory Days | Days | 32 | 104 | 31.0% | |
Debtors Days | Days | 47 | 66 | 70.8% | |
Net fixed assets | Rs m | 991 | 20,368 | 4.9% | |
Share capital | Rs m | 141 | 253 | 55.9% | |
"Free" reserves | Rs m | 2,373 | 30,971 | 7.7% | |
Net worth | Rs m | 2,514 | 31,224 | 8.1% | |
Long term debt | Rs m | 3 | 1,409 | 0.2% | |
Total assets | Rs m | 4,158 | 45,507 | 9.1% | |
Interest coverage | x | 12.6 | 30.0 | 42.1% | |
Debt to equity ratio | x | 0 | 0 | 3.0% | |
Sales to assets ratio | x | 1.5 | 0.8 | 182.1% | |
Return on assets | % | 6.7 | 10.1 | 65.9% | |
Return on equity | % | 9.7 | 14.2 | 68.4% | |
Return on capital | % | 16.9 | 17.3 | 97.8% | |
Exports to sales | % | 3.6 | 45.9 | 7.8% | |
Imports to sales | % | 0.5 | 16.6 | 3.0% | |
Exports (fob) | Rs m | 225 | 17,308 | 1.3% | |
Imports (cif) | Rs m | 31 | 6,266 | 0.5% | |
Fx inflow | Rs m | 225 | 17,308 | 1.3% | |
Fx outflow | Rs m | 71 | 6,266 | 1.1% | |
Net fx | Rs m | 154 | 11,042 | 1.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 173 | 4,923 | 3.5% | |
From Investments | Rs m | 97 | -1,563 | -6.2% | |
From Financial Activity | Rs m | -307 | -1,832 | 16.8% | |
Net Cashflow | Rs m | -38 | 1,528 | -2.5% |
Indian Promoters | % | 65.4 | 45.9 | 142.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 11.4 | 32.5% | |
FIIs | % | 5.2 | 25.3 | 20.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 25.8 | 17.4 | 148.3% | |
Shareholders | 12,723 | 36,892 | 34.5% | ||
Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare TTK HEALTHCARE With: PANACEA BIOTECH BIOCON FULFORD INDIA NATCO PHARMA AJANTA PHARMA
Compare TTK HEALTHCARE With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets nosedived and registered sharp losses in yesterday's volatile session following a strong second wave of Covid-19 in the country.
For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended December 2020, TTK HEALTHCARE has posted a net profit of Rs 77 m (up 71.7% YoY). Sales on the other hand came in at Rs 2 bn (up 8.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended December 2019, TTK HEALTHCARE has posted a net profit of Rs 45 m (down 8.3% YoY). Sales on the other hand came in at Rs 2 bn (up 11.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
Those who don't learn from financial history are doomed to lose their money.
More